These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34109776)

  • 1. Inhibitors of ADAM10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.
    Pece R; Tavella S; Costa D; Varesano S; Camodeca C; Cuffaro D; Nuti E; Rossello A; Alfano M; D'Arrigo C; Galante D; Ravetti JL; Gobbi M; Tosetti F; Poggi A; Zocchi MR
    Haematologica; 2022 Apr; 107(4):909-920. PubMed ID: 34109776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells.
    Tosetti F; Venè R; Camodeca C; Nuti E; Rossello A; D'Arrigo C; Galante D; Ferrari N; Poggi A; Zocchi MR
    Oncoimmunology; 2018; 7(5):e1421889. PubMed ID: 29721369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugate Made of Zoledronic Acid and the Anti-CD30 Brentuximab-Vedotin Exert Anti-Lymphoma and Immunostimulating Effects.
    Morelli F; Matis S; Benelli R; Salvini L; Zocchi MR; Poggi A
    Cells; 2024 May; 13(10):. PubMed ID: 38786084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.
    Hansen HP; Trad A; Dams M; Zigrino P; Moss M; Tator M; Schön G; Grenzi PC; Bachurski D; Aquino B; Dürkop H; Reiners KS; von Bergwelt-Baildon M; Hallek M; Grötzinger J; Engert A; Paes Leme AF; Pogge von Strandmann E
    Oncotarget; 2016 May; 7(21):30523-35. PubMed ID: 27105521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
    Alperovich A; Younes A
    Cancer J; 2016; 22(1):23-6. PubMed ID: 26841013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
    Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM
    Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD30 Antibodies for Hodgkin lymphoma.
    Foyil KV; Bartlett NL
    Curr Hematol Malig Rep; 2010 Jul; 5(3):140-7. PubMed ID: 20446121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing.
    Zocchi MR; Camodeca C; Nuti E; Rossello A; Venè R; Tosetti F; Dapino I; Costa D; Musso A; Poggi A
    Oncoimmunology; 2016 May; 5(5):e1123367. PubMed ID: 27467923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma.
    Hansen HP; Paes Leme AF; Hallek M
    Front Immunol; 2020; 11():398. PubMed ID: 32296414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
    Chen R; Chen B
    Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
    Rinaldi I
    Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.
    Forero-Torres A; Fanale M; Advani R; Bartlett NL; Rosenblatt JD; Kennedy DA; Younes A
    Oncologist; 2012; 17(8):1073-80. PubMed ID: 22855426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
    Othman T; Herrera A; Mei M
    Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hodgkin lymphoma: Focus on evolving treatment paradigms.
    Roswarski JL; Longo DL
    Best Pract Res Clin Haematol; 2023 Dec; 36(4):101510. PubMed ID: 38092470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
    Bhatt G; Maddocks K; Christian B
    Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.
    Ju W; Zhang M; Wilson KM; Petrus MN; Bamford RN; Zhang X; Guha R; Ferrer M; Thomas CJ; Waldmann TA
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1624-9. PubMed ID: 26811457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?
    Goyal SD; Bartlett NL
    Curr Hematol Malig Rep; 2012 Sep; 7(3):179-85. PubMed ID: 22669711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
    Younes A; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Ramchandren R; Bartlett NL; Cheson BD; de Vos S; Forero-Torres A; Moskowitz CH; Connors JM; Engert A; Larsen EK; Kennedy DA; Sievers EL; Chen R
    J Clin Oncol; 2012 Jun; 30(18):2183-9. PubMed ID: 22454421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.